ArticleRSC advances2023
New 1,3,4-thiadiazoles as potential anticancer agents: pro-apoptotic, cell cycle arrest, molecular modelling, and ADMET profile.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Synthesis, anti-proliferative evaluation, DFT,RSC advances · 2026Article
- Iodine/TBAB-promoted oxidative cyclization: an efficient approach to thiadiazoles.RSC advances · 2026Article
- Advances in 1,3,4-thiadiazole-based cholinesterase inhibitors: toward novel therapeutics for Alzheimer's disease.Molecular diversity · 2026Review
- Synthesis, computational studies, and biological evaluation of novel cyanoacrylamides as potential anticancer agents.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- New benzochromene-based compounds as potential EGFR-TK inhibitors: synthesis, anti-proliferative activity, molecular docking studies, and ADME profiles.RSC advances · 2026Article
- NovelPharmaceuticals (Basel, Switzerland) · 2026Article
- Synthesis and characterization of FeCuAlOScientific reports · 2025Article
- Antimicrobial Activity of 1,3,4-Thiadiazole Derivatives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Synthesis and in silico studies of new thiophene-isoquinolinone hybrids as potential larvicides against Culex pipiens.Scientific reports · 2025Article
- Recent Developments of 1,3,4-Thiadiazole Compounds as Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- 2-[(5-Methyl-1,3,4-thia-diazol-2-yl)sulfan-yl]-IUCrData · 2025Article
- Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors.Future medicinal chemistry · 2025Article
- Rational design and synthesis of new pyrrolone candidates as prospective insecticidal agents against Culex pipiens L. Larvae.Scientific reports · 2024Article
- Discovery of a 6-Aminobenzo[ACS pharmacology & translational science · 2024Article
- Redox homeostasis in human renal cells that had been treated with amphotericin B in combination with selected 1,3,4-thiadiazole derivatives.Pharmacological reports : PR · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of novel 1,3,4-thiadiazoles was synthesized
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.